FDA approves new ALS drug tested in clinical trial at UF
AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.
AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.
Learn how a new fund is propelling the ALS research of Drs. Emily Plowman and James Wymer.
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
UF was the No. 2 enroller of patients for multisite ALS trial.
Dr. James Wymer among national team of researchers to identify novel pathway for potential treatment of the disfiguring condition, neurofibromatosis 1.
The seventh annual 2018 Celebrating Distinction event honored faculty named to endowed professorships, chairs.
Following legendary physicist Stephen Hawking’s passing after battling ALS for more than 50 years, Dr. James Wymer discusses this unforgiving disease.